US09058V1035
US09058V1035
BioCryst Pharmaceuticals, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 874.837.000 | 450.712.000 | 94.1% |
| Cost of Revenue | 19.075.000 | 12.269.000 | 55.5% |
| Gross Profit | 855.762.000 | 438.443.000 | 95.2% |
| 514.773.000 | 440.986.000 | 16.7% | |
| Operating Income | 340.989.000 | -2.543.000 | 13508.9% |
| Pretax Income | 267.391.000 | -86.954.000 | 407.5% |
| Net Income Common Stockholders | 263.861.000 | -88.881.000 | 396.9% |
| -- | -- | -- | |
| -- | -- | -- |